Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute Effects of R- and S-MDMA in Healthy Subjects
NCT05277636Phase 1Completed
- Sponsor
- University Hospital Basel
- Start
- Oct 2022
- Primary completion
- Jan 2024
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of R-MDMA and s-3,4-methylenedioxymethamphetamine in post-traumatic stress disorder (PTSD) (5 arms), sponsored by University Hospital Basel. Primary endpoints: Subjective effects I at 18 months and Subjective effects II at 18 months. Started Oct 2022; status: completed.
02
Drugs
R-MDMAs-3,4-methylenedioxymethamphetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05277636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05277636.